N/A N=10 CrYobiopsy With Radial UltraSound Guidance
Pulmonary Disease
Primary: Time to Achieve Hemostasis After Obtaining Cryobiopsy — 146.55; 132.25 seconds — p=0.7878
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=144 HW006 LATERAL Thoracotomy
Left Sided Heart Failure
Primary: Subject is Alive on Original Device, Transplanted, or Explanted for Recovery at 6 Months — 128 Participants — p=0.0003
N/A N=1,463 Virtual Gout Clinic
Gout
Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
Phase 2 N=41 RFT-5-dgA in Patients With Metastatic Melanoma
Metastatic Melanoma
Primary: Clinical Responses Can be Obtained in Following Administration of RFT5-dgA
N/A N=80 Mechanisms of Mindfulness for Smoking Cessation
Smoking Cessation
Primary: Change From Baseline in Blood Oxygen Level Dependent (BOLD) Signal — 16.1; 18.6 BOLD signal — p=0.92
Early Phase 1 N=40 Using an Internet Study to Improve Adherence for Psoriasis Patients
Psoriasis
Primary: Measured MEMS Adherence- Number of Days With a Correct Number of Doses Taken — 15.14; 20.22 Days
Phase 3 N=44 Airway Effects of Tiotropium in Patients With COPD
COPD · LUNG DISEASES, OBSTRUCTIVE
Primary: Peripheral Airways Resistance (R5-R20) — 0.23; 0.2; 0.16 kPa/l/s
Phase 4 N=117 Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)
Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After End of Treatment (SVR12) — 94.3; 95.3 Percentage of Participants
Phase 3 N=10 A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1) — 9 Participants
N/A N=20 Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in the Mean Daily Walking Distance Over 7 Consecutive Days — 754.2; -1160 steps
Phase 1 N=31 A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1
Malaria
Primary: Safety and Tolerability of Administration of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Solicited Local and Systemic Adverse Events…
N/A N=112 Reveal LINQ™ Heart Failure
Heart Failure
Primary: Number of Participants With Reveal Device Experiencing an Initial Acute Decompensated Heart Failure (ADHF) Event — 36 participants
N/A N=152 Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
Bronchiolitis · Bronchiolitis, Viral · RSV Infection
Primary: The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling — 124; 60; 0; 0 Sampling visits
Phase 3 N=64 Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Thromboembolism of Vein VTE in Colorectal Cancer · Thromboembolism of Vein in Pancreatic Cancer · Thromboembolism of Vein in Non-small Cell Lung Cancer
Primary: Percent Change in D-dimer Value — 9.9; -21.9 percent change — p=0.92
N/A N=30 Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty With Attune Knee System - Phase 2
Total Knee Arthroplasty · Osteoarthritis
Primary: Femoro-tibial Kinematics - Lateral Anterior/Posterior Motion — -5.81; -0.1; 0.58 mm